Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Jacobs Solutions Inc (J) Q1 2025 Earnings Call Highlights: Strong Backlog Growth and Strategic ...

In This Article:

  • Total Gross Revenue: Increased over 4% in Q1.

  • Adjusted Net Revenue: Rose over 5% year-over-year.

  • GAAP EPS: Negative $0.10, impacted by a $1.16 loss from investment in Amentum.

  • Adjusted EPS: $1.33, an 8% decrease compared to the previous year.

  • Adjusted EBITDA: $282 million, a 24% year-on-year increase.

  • Adjusted EBITDA Margin: 13.5%, increased by approximately 200 basis points year-over-year.

  • Consolidated Backlog: Increased 19% year-over-year, totaling $21.8 billion.

  • Book-to-Bill Ratio: 1.4x for Q1; trailing 12-month ratio at 1.3x.

  • Free Cash Flow: $97 million for Q1.

  • Share Repurchases: $202 million in Q1, with a new $1.5 billion authorization approved.

  • Dividend: $0.32 per share, representing 10% year-over-year growth.

  • Adjusted EPS Guidance: Raised to $5.85 to $6.20 for fiscal '25.

Release Date: February 04, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Total gross revenue increased over 4% in Q1, with adjusted net revenue rising over 5%.

  • Adjusted EBITDA for Q1 was $282 million, representing a 24% year-on-year increase.

  • Consolidated backlog increased 19% year-over-year in Q1, with a trailing 12-month book-to-bill ratio of 1.3x.

  • Significant contract wins in critical infrastructure, including the River Torrens to Darlington project in South Australia and the BusConnects Dublin program.

  • Strong performance in the Water and Environmental segment, with double-digit revenue growth across all major geographies.

Negative Points

  • GAAP EPS was negative $0.10, impacted by a $1.16 mark-to-market loss on investment in Amentum.

  • Adjusted EPS decreased by 8% compared to the previous year, primarily due to an unfavorable tax comparison.

  • Life sciences and advanced manufacturing segment showed mixed results, with life sciences strong but advanced manufacturing soft.

  • Free cash flow for Q1 was $97 million, with a more back half-weighted cadence expected for the full year.

  • Exposure to potential federal spending cuts, though less than 10% of business is tied to federal agencies.

Q & A Highlights

Q: Can you discuss the sentiment from your US government and commercial customers and how it reflects in your backlog? A: Bob Pragada, Chair and CEO, stated that customer sentiment remains positive despite the political narrative. The company is seeing double-digit pipeline growth across end markets, and the cadence of awards is reflected in backlog growth, indicating no dramatic shifts in customer behavior.

Q: What initiatives are contributing to margin improvement this year, and what can we expect in the back half? A: Venk Nathamuni, CFO, highlighted ongoing cost controls, operating leverage from revenue growth, and a global delivery model as key contributors to margin improvement. The company expects a slight dip in Q2 margins due to holiday timing but anticipates reaching a 13.8% to 14% margin for the full year.